PatientsVille.com Logo

Non-small and Taxotere

PatientsVille

Non-small Symptoms and Causes

Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk.

Common symptoms of lung cancer include

  • A cough that doesn't go away and gets worse over time
  • Constant chest pain
  • Coughing up blood
  • Shortness of breath, wheezing, or hoarseness
  • Repeated problems with pneumonia or bronchitis
  • Swelling of the neck and face
  • Loss of appetite or weight loss
  • Fatigue

Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute

Check out the latest treatments for non-small

non-small treatment research studies

Taxotere clinical trials, surveys and public health registries


Find Drug Side Effect reports



Taxotere Side Effects

Dyspnoea (353)
Diarrhoea (295)
Interstitial Lung Disease (276)
Pyrexia (227)
Febrile Neutropenia (202)
Neutropenia (196)
Nausea (194)
Dehydration (193)
Asthenia (154)
Vomiting (146)
Hypotension (132)
Abdominal Pain (131)
Anaemia (122)
Fatigue (121)
White Blood Cell Count Decreased (112)
Respiratory Failure (106)
Haemoglobin Decreased (97)
Pneumonia (95)
Neutrophil Count Decreased (92)
Renal Failure (88)
Hypokalaemia (86)
Mucosal Inflammation (86)
Death (85)
Cardiac Arrest (83)
Erythema (80)
Renal Failure Acute (77)
Blood Creatinine Increased (77)
Back Pain (77)
Sepsis (75)
Dizziness (72)
Pleural Effusion (72)
Chest Pain (71)
Disseminated Intravascular Coagulation (71)
Oedema Peripheral (70)
Pulmonary Embolism (68)
Flushing (68)
Hyponatraemia (67)
Cough (67)
Infusion Related Reaction (66)
Anorexia (64)
Blood Pressure Decreased (62)
Leukopenia (56)
Acute Respiratory Distress Syndrome (56)
Pain (55)
Loss Of Consciousness (55)
Bone Marrow Failure (54)
Malaise (53)
Confusional State (53)
Chest Discomfort (50)
Aspartate Aminotransferase Increased (50)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

76 year old husband was intoduced to Benefiber gradually, but now he has not had a bowel movement for 2 days. I don't know if I can give him a small dose of milk of magnesia.

i had small ring worms ao my back what should i do

Unresponsive to 5mg/kg q 8wks; increased to 10mg/kg q6wks. After 3 doses at that strength noted fatigue, occasional night sweats, joint aches, sudden onset of chest pain and dyspnea (pleurisy, small pleuraleffusion) Had just taper

<b>After taking this drug I suffered abdominal pain with diarrhea after eating even small amounts, pain developed with the urge to get to a toilet at once. I had a full blood and liver test and a stool test and all was normal.&nbs

1-09 When I took a very small amount, 2.5 mg, it just relaxed me. I took it to get on the plane. But when I took 5 or 10 (rx'd by my doc for muscle spasms that woke me up) I had nightmares. I seldom if ever had nightmares, and never about people

76 year old husband introduced to Benefiber gradually. Now is constipated for 2 days. Don't know what to give him other than a small dose of milk of magnesia.

@ Sue Yost: The content of one capsule is very small. Haven't you heard the vibration during your application? This is a good evidence if the capsules were indeed empty. Are you going to file a complaint?

A kind of confusion, thinking way is different from others....feel like all are talking about me...and then going into depression for small reasons

After 5 doses - experienced extreme blood shot eyes and a tender head to the touch. Symptoms totally gone after a day&amp;1/2. Wow, didn't see that in the small print.

After several small sips of Benylin DM-E ( regular strength), an episode of transient global amnesia. Same had occurred many years earlier after absorbing a number of throat lozenges on an airplane

Non-small Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel * Sunitinib;   Drug: Docetaxel
Outcome Measures: Primary: CEC/CEP spikes induced by MTD docetaxel in patients treated with docetaxel/sunitinib relative to docetaxel monotherapy;   Response rate and length of treatment holidays relative to docetaxel monotherapy
2 Recruiting Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
Outcome Measures: assess clinical tumor response to neoadjuvant chemotherapy (Taxotere and AC) and to validate that clinical response strongly correlates with prospectively-determined regimen-specific gene expression profiles of sensitivity and resistance;   determine time to tumor progression; median overall survival; and document toxicities associated with the chemotherapy regimens
3 Unknown  Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: docetaxel;   Drug: docetaxel, cisplatin;   Drug: docetaxel, S-1
Outcome Measures: response rate;   time to progression
4 Recruiting A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Fulvestrant
Outcome Measures: Progression Free Survival;   Overall Response Rate;   Overall Survival
5 Recruiting Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions: Recurrent;   Head and Neck Cancer
Interventions: Radiation: SBRT;   Drug: Cetuximab;   Drug: Docetaxel
Outcome Measures: Locoregional progression-free survival (PFS) of previously-irradiated patients with SCCHN treated with SBRT, cetuximab, and docetaxel;   Acute and late toxicities associated with the above therapy
6 Recruiting Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: docetaxel;   Procedure: prostate biopsy;   Other: laboratory biomarker analysis;   Drug: phenelzine sulfate
Outcome Measures: Proportion of patients who experience a PSA decline of at least 30%;   Duration of progression free survival after initiation of combination phenelzine and docetaxel therapy;   Response rate in measurable disease by RECIST criteria;   Maximum change in PSA;   Toxicity of the regimen;   Time to death from all causes;   Frequency of MAOA overexpression in CRPC tumors that are progressing on docetaxel;   HIF-1alpha expression in circulating tumor cells as a potential measure of MAO and activity;   MAOA expression in circulating tumor cells and comparison to biopsy MAOA expression
7 Recruiting Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel, Reolysin and Prednisone;   Drug: Docetaxel and Prednisone
Outcome Measures: Disease Progression;   Effect of Docetaxel and Reolysin on circulating tumour cells;   PSA change rate;   Objective Response;   Overall Survival;   Determine patient tolerability and toxicity of Reolysin and Docetaxel in combination;   Prognostic/Predictive molecular response
8 Recruiting Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients
Condition: Prostate Cancer
Interventions: Drug: Docetaxel every 3 weeks + Prednisone;   Drug: Docetaxel weekly+ Prednisone
Outcome Measures: Feasibility of 2 different protocols of Docetaxel chemotherapy;   Overall Survival;   Geriatric evaluation;   Number of patients with Adverse Events;   Quality of Life;   Vital signs measurement;   Prostate-specific antigen (PSA) measurements
9 Recruiting Docetaxel and Lycopene in Metastatic Castration-resistant Prostate Cancer
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: Lycopene and Docetaxel
Outcome Measures: Determination of the Maximum Tolerated Dose of Lycopene when given in combination with docetaxel;   IGF1 signaling inhibition at MTD;   Pharmacokinetic assessment of docetaxel and lycopene;   Assessment of plasma levels of IL6, IGF1, IGF-2, and IGFBP3; and IGF1R level
10 Recruiting Taxotere Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
Condition: Carcinoma, Non Small Cell Lung
Interventions: Drug: Taxotere;   Drug: Pemetrexed
Outcome Measures: Progression Free Survival;   Overall Survival (months from the beginning of first cycle chemotherapy);   Safety Profile;   Response rate
11 Recruiting Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients
Condition: Advanced Cancer
Interventions: Drug: DT-LM;   Drug: docetaxel
Outcome Measures: The safety and tolerability;   Assessment of pharmacokinetics of DT-LM and Taxotere: AUC and Cmax;   Objective tumour response according to RECIST
12 Unknown  A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Taxotere;   Drug: Celecoxib
Outcome Measures: Determine the effect of Taxotere and celecoxib on PSA and objective response in patients with HRPC;   Evaluate the toxicity of the combination of celecoxib and Taxotere in patients with stage D3 prostate cancer.;   Determine the effects of this regimen on quality of life.;   Determine the survival of the patients treated
13 Recruiting Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Docetaxel;   Dietary Supplement: Lycopene
Outcome Measures: PSA response (proportion of subjects achieving a >= 50% reduction in PSA from baseline);   Objective response rate as assessed by RECIST criteria in either visceral or lymph node metastases;   Time to PSA progression;   Toxicity of combined docetaxel + lycopene therapy
14 Recruiting Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Condition: Sarcoma
Interventions: Drug: Docetaxel (Taxotere);   Drug: Irinotecan
Outcome Measure: CT or MRI image of tumor
15 Recruiting Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: cisplatin;   Drug: docetaxel;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy
Outcome Measures: Disease-free survival (DFS) (Phase II);   Overall survival (OS) (Phase III);   Local-regional failure (LRF);   Distant metastasis (DM);   Patterns of cancer failure (local, regional, distant);   Acute toxicity profiles during and at completion of treatment, graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0;   Late toxicity profiles, graded according to the NCI CTCAE version 4.0;   Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N) scores;   MD Anderson Symptom Inventory - Head & Neck (MDASI-HN) scores;   MD Anderson Dysphagia Inventory (MDADI) scores;   EuroQol (EQ-5D) scores;   Quality adjusted life year (QALY);   Translational research analysis
16 Not yet recruiting Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
Conditions: Chemotherapeutic Agent Toxicity;   Lung Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Drug: Anvirzel;   Behavioral: Questionnaires
Outcome Measures: Maximum Tolerated Dose (MTD) of sublingual (SL) dosing of Anvirzel in combination with chemotherapy;   Pharmacokinetics of carboplatin and docetaxel when administered concurrently with SL Anvirzel;   Anti-inflammatory effects of SL Anvirzel during carboplatin and docetaxel chemotherapy;   Immunomodulatory effects of SL Anvirzel during carboplatin and docetaxel chemotherapy;   Symptoms and quality-of-life outcomes based on MDASI-LC and SF-12 scores;   Grade 3-4 toxicities at each course according to NCI Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0
17 Recruiting A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Conditions: Bone Metastases;   Castration-Resistant Prostate Cancer
Interventions: Drug: Alpharadin® (Radium-223 dichloride) + docetaxel;   Drug: Docetaxel
Outcome Measures: Dose-escalation: Assessment of dose-limiting toxicities;   Expanded safety cohort: Safety of combining Alpharadin® with docetaxel (incidence and severity of adverse events and serious adverse events, changes from baseline in laboratory variables, vital signs and physical examination);   Signs of long-term radiation toxicity: incidence of manifestations of potential late toxicity, such as new primary cancers and bone marrow changes (acute myelogenous leukaemia, myelodysplastic syndrome, and aplastic anaemia);   Exploratory efficacy measurements of Alpharadin® in combination with docetaxel versus docetaxel alone such as changes in bone markers, PSA and CTC, time to progression and overall survival;   Exploratory patient self-reporting of pain intensity
18 Not yet recruiting VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: VEGFR/PDGFR dual kinase inhibitor X-82;   Drug: docetaxel;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography/computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: Incidence of toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (Pharmacodynamic study);   Changes in the FLT PET/CT vascular parameters for VEGF/PDGF dual kinase inhibitor X-82;   Changes in the FLT PET/CT vascular parameters for the combination of VEGFR/PDGFR dual kinase inhibitor X-82 and docetaxel;   Disease response assessed by the RECIST 1.1;   Changes in VEGF;   Pharmacokinetic parameters of VEGFR/PDGFR dual kinase inhibitor X-82
19 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
Outcome Measures: Overall Survival;   Progression-free survival;   Overall Response Rate;   Safety
20 Recruiting Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: docetaxel;   Drug: pasireotide;   Drug: prednisone
Outcome Measures: Occurrence of adverse events and the associated grade per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to identify the maximum tolerated dose (MTD) of pasireotide in combination with docetaxel and prednisone;   All specific types of toxicity as assessed via NCI CTCAE version 4.0;   Measurements of tumor using Response Evaluation Criteria In Solid Tumors (RECIST) criteria before and after treatment with the combination of pasireotide in combination with docetaxel;   Percentage prostate-specific antigen (PSA) decline noted;   Time to Progression (TTP);   Overall Survival (OS);   Pharmacokinetics (PK) parameters;   Measurement of levels of IGF-1, serum chromogranin A (SCA), and neuron specific enolase (NSE), pre-therapy, post-therapy, and the change between time points and association with duration of TTP and OS;   Measurements of CTC counts pre-therapy, post-therapy, and the change between time-points and association with duration of TTP and OS